AC
DGX icon

Ascend Capital’s Quest Diagnostics DGX Stock Holding History

Ascend Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-43,990
Closed -$2.67M – 206
2013
Q2 		$2.67M Buy
+43,990
New +$2.62M 0.11% 141

Other funds holding DGX

LTI
Laffer Tengler Investments Nashville, Tennessee $677M AUM 27.58% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ascend Capital's DGX Position: Q3 2013 in Review

Ascend Capital sold out of Quest Diagnostics (DGX) in Q3 2013, closing a stake of 43,990 shares — an estimated $2.67M sold.

Ascend Capital first reported a position in DGX in Q2 2013 and held it in 1 quarter. The position peaked at $2.67M in Q2 2013. 425 funds tracked by Wall St. Rank hold DGX as of Q3 2013.

  • Ascend Capital reported no remaining Quest Diagnostics position as of Q3 2013 after selling out during the quarter.
  • Ascend Capital sold 43,990 Quest Diagnostics shares in Q3 2013, an estimated $2.67M.
  • Ascend Capital first reported a position in Quest Diagnostics in Q2 2013 and held it in 1 quarter.
  • Ascend Capital's Quest Diagnostics position peaked at $2.67M in Q2 2013.
  • 425 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2013.

Based on Ascend Capital's 13F filing for Q3 2013, filed 13 Nov 2013.